The announcement will be followed by a live webcast at 2:00 p.m. PT/5:00 p.m. ET, in which Exelixis management will discuss the second quarter financial results and give a general update on the company's financial position and business, including its development pipeline and corporate strategy. The webcast may be accessed in the Event Calendar page under Investors at www.exelixis.com.

An archive of this webcast will be available until September 5, 2008. Access numbers for this replay are 1-888-286-8010 (domestic) and 1-617-801-6888 (international); the replay passcode number is 20987321.

About Exelixis

Exelixis, Inc. is a development-stage biotechnology company dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 3, phase 2, and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb Company, Genentech, Wyeth Pharmaceuticals and Daiichi-Sankyo. For more information, please visit the company's web site at www.exelixis.com.

SOURCE: Exelixis, Inc.

Exelixis, Inc.
Investor:
Charles Butler, 650-837-7277
Senior Director
Corporate Communications & Investor Relations
cbutler@exelixis.com
or
Media:
Soleil Maxwell Harrison, 650-837-7012
Senior Manager
Corporate Communications
sharrison@exelixis.com